Are AstraZeneca shares worth buying?

AstraZeneca shares have a high price-to-earnings ratio, but I don’t think you should let that put you off this FTSE 100 (INDEXFTSE:UKX) stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the stock market crash in March, investors have become wary of which shares to buy. This has resulted in some sectors being avoided and others seeing high demand. Unloved sectors include travel, hospitality, oil and finance, while loved sectors include technology and pharmaceuticals. This has led to a lot of high-quality shares with ridiculously high price-to-earnings ratios (P/E). Think AstraZeneca (LSE:AZN) with its earnings multiple of 104, Avon Rubber at 86 and Games Workshop at 45.

As I consider buying these shares, I worry if a market correction occurs, I’ll have paid too much at a price point that’s unsustainable. This problem is not unique to the UK, it’s even more prevalent in the US, where Tesla has reached an astronomical P/E of 959.

A high P/E should signal quality

However, successful British fund manager Terry Smith recently said that a high P/E will not necessarily lead to future disappointment. This is because many companies doing well today previously had a high P/E and it would have been a mistake to avoid them for that reason alone. When a company looks strong and offers consumers and shareholders value, it could continue to do so.

A price-to-earnings ratio is calculated by dividing the current stock price by its earnings-per-share (EPS). When a company’s earnings increase, then the P/E will usually reduce. 

The reason a company achieves a high P/E in the first place is because a deluge of investors buying it drives its share price up. If that many people believe in the stock, then surely this should signal a quality company? I think that’s what’s happened in AstraZeneca’s case.

Is the AstraZeneca share price too expensive?

The AstraZeneca share price has skyrocketed this year as it gets set to battle Covid-19 via its vaccine collaboration with Oxford University. AstraZeneca has a fantastic array of medicines already available and many more in the pipeline. It provides diversification through its variety of treatment types, and is enjoying product sales growth. It also offers a dividend yield of 2.5%, which may tempt long-term investors looking to add dividend stocks to their portfolios.

The trouble with pharma companies is they’re up against several factors, not least being a competitive marketplace. The economic backdrop can significantly influence share price volatility. And there’s always the risk of failed trials, adverse reactions to drugs and massive costs in research and development. Last week AstraZeneca halted its Covid-19 vaccine trial to investigate a bad reaction in one of its participants. The trial has now resumed, but it highlights the risks involved when dealing with people’s health.

AstraZeneca’s R&D department is world leading and advances in technology are helping it break down barriers. It’s pumping a lot of money into R&D, which stands to pay off handsomely if it results in ground-breaking medicines to tackle the world’s worst health problems.

AstraZeneca shares have high price-to-earnings ratio
Source: AstraZeneca – New Cambridge R&D Centre and Global HQ

So, are AstraZeneca shares worth buying? I think for the long term they probably are. I do think they’re expensive today, but risk aside, it’s an excellent company. If you really believe in a business and like everything it offers, I don’t think you should let its high price-to-earnings ratio put you off. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »